Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

• Main Authors: Narmeen Mallah (Author), Sonia Ares-Gómez (Author), Jacobo Pardo-Seco (Author), Alberto Malvar-Pintos (Author), María-Isolina Sa (Author), Olaia Pérez-Martínez (Author), María-Teresa (Author), Nuria Suárez-Gaiche (Author), Rolf Kramer (Author), Jing Jin (Author), Leticia Platero-Alonso (Author), Rosa-María A (Author), Olga-Mar (Author), Victoria Nartallo-Penas (Author), Susana Mirás-Carballal (Author), Marta Piñeiro-Sotelo (Author), Juan-Manuel Go (Author), Carmen Rodríguez-Tenreiro (Author), Irene Rivero-Calle (Author), Antonio Salas (Author), Carmen Durán-Parrondo (Author), Federico Martinón-Torres (Author)
• Format: Bog
• Udgivet: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

ABSTRACTNirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023. It aims to evaluate nirsevimab effectiveness against RSV-related hospitalizations lower respiratory tract infections (LRTI)...